At 17.6% CAGR, the SAM Medical Robots Market is projected to be worth US$ 1,483.48 million by 2028, says Business Market Insights         

According to Business Market Insights’ research, the SAM medical robots market was valued at US$ 560.98 million in 2022 and is expected to reach US$ 1,483.48 million by 2028, registering an annual growth rate of 17.6% from 2022 to 2028.  Development of microswimmers and evolution of nanorobots for cancer treatment are the critical factors attributed to the market expansion.                

Nanorobots play an important role in bio-medicine, majorly for the treatment of cancer and cerebral aneurysm, removal of kidney stones, and the elimination of defected parts in the DNA structure. The current stages of medical technologies and therapy tools are used to treat cancer successfully. For successful treatment, efficient drug delivery is important to decrease the side effects of chemotherapy. Nanorobots with implanted chemical biosensors are used to detect the tumor cells in the early stages of cancer development inside a patient’s body. Nanosensors are utilized to find the intensity of E-cadherin signals. In many cancer cases, drugs can cause side effects because they can’t differentiate between cancer cells and healthy ones. The nanorobots target only tumors and don’t cause clotting elsewhere in the body. Therefore, side effects can be avoided in the cancer treatment. Manufacturers and scientists have been investing in innovative technological developments. So, evolution of nanorobots for cancer treatment is expected to drive the market during forecast period.

On the contrary, high cost of surgical procedures and installation hurdles the growth of SAM medical robots market.  

Based on product, the SAM medical robots market is segmented into surgical robots, hospital & pharmacy robots, rehabilitation robots, non-invasive radiosurgery robots, and others. The surgical robots segment held 36.7% market share in 2022, amassing US$ 206.03 million. It is projected to garner US$ 532.70 million by 2028 to expand at 17.2% CAGR during 2022–2028.    

Based on application, the SAM medical robots market is segmented into laparoscopy, neurology, orthopedics, gynecology, urology, cardiology, and others. The laparoscopy segment held 36.0% market share in 2022, amassing US$ 201.80 million. It is projected to garner US$ 538.56 million by 2028 to expand at 17.8% CAGR during 2022–2028.   

Based on end user, the SAM medical robots market is segmented into hospitals, ambulatory surgical centers and others. The hospitals segment held 58.2% market share in 2022, amassing US$ 326.66 million. It is projected to garner US$  877.06 million by 2028 to expand at 17.9% CAGR during 2022–2028.      

Based on country, the SAM medical robots market has been categorised into Brazil, Argentina, and rest of SAM. Our regional analysis states that Brazil captured 58.8% market share in 2022. It was assessed at US$ 329.63 million in 2022 and is likely to hit US$ 878.38 million by 2028, exhibiting a CAGR of 17.7% during the forecast period.        

Key players dominating the SAM medical robots market are Accuray Incorporated, ARxIUM, Auris Medical, Ekso Bionics, Hocoma AG, Intuitive Surgicals, Kirby Lester, Medtronic, Omnicell Inc., and Stryker Corporation among others.           

• In May 2022, Auris Health announced collaboration with Ethicon to enable bronchoscopic ablation of lesions in the lung. Companies collaborated to integrate the Neuwave™ flexible microwave ablation technology with Auris’s Monarch™ platform for robotic bronchoscopy

• In Sep 2020, Ekso Bionics has unveiled EVO, an endurance-boosting assistive Upper Body Exoskeleton that alleviates the burden of repetitive work. The EVO Upper Body Exoskeleton is designed to reduce fatigue and shoulder and back muscle strain, with the goal of eliminating work-related injuries to the neck, shoulder, and back.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com